3 Branded Generics Exporter, Latin America Focused Drug Maker and Largest Indian Pharmaceutical Company Stocks With a Strong Future Roadmap: Ajanta Pharma, Caplin Point Laboratories and Sun Pharma

Africa, Latin America and specialty drug stocks bring together companies with a visible plan for the years ahead. Ajanta Pharma, Caplin Point Laboratories and Sun Pharma cover a branded generics exporter, a Latin America focused drug maker and the largest Indian pharmaceutical company.

This list covers three Africa, Latin America and specialty drug stocks with complete current figures: Ajanta Pharma, Caplin Point Laboratories and Sun Pharma. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Africa, Latin America and Specialty Drug Stocks?

Africa, Latin America and specialty drug stocks are listed pharmaceutical companies that sell branded generics in India, Africa, Asia and Latin America and also build specialty and complex generics for regulated markets. Their earnings depend on product launches, regulatory approvals, pricing and currency.

Africa, Latin America and Specialty Drug Stocks at a Glance

On valuation, Caplin Point Laboratories and Sun Pharma trade at a P/E below the industry P/E, while Ajanta Pharma trades above it, which reflects the growth the market already expects. Readers comparing Africa, Latin America and specialty drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in Africa, Latin America and specialty drug stocks can use the coming numbers to test whether growth is holding.

Why Do Africa, Latin America and Specialty Drug Stocks Have a Strong Roadmap in India?

Africa, Latin America and specialty drug stocks have a strong roadmap in India because wider access to medicines in emerging markets, specialty launches and a strong domestic prescription base keep widening the market for Indian pharmaceutical companies.

• Emerging markets. Branded generics reach fast-growing regions.
• Specialty launches. Skin and eye care products add value.
• Domestic base. Doctors prescribe trusted brands.

Why Ajanta Pharma Features Among These Africa, Latin America and Specialty Drug Stocks

Among the Africa, Latin America and specialty drug stocks on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.

In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%.

Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.

Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

What to watch: Monitor the pace of new launches in branded markets and the momentum in the United States generics business.

Why Caplin Point Laboratories Features Among These Africa, Latin America and Specialty Drug Stocks

Among the branded generics and specialty medicines shares on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.

The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0.

Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore.

Roadmap: The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

What to watch: Follow new US product approvals and currency trends in Latin American markets.

Why Sun Pharma Features Among These Africa, Latin America and Specialty Drug Stocks

Among the three companies on this list, Sun Pharmaceutical Industries is India's largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.

Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%.

In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.

Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.

What to watch: Track specialty product launches, United States approvals and domestic prescription trends.

Ajanta Pharma vs Caplin Point Laboratories vs Sun Pharma on Key Financials

The table below sets the three Africa, Latin America and specialty drug stocks side by side on revenue, profit and margin, using reported figures.

Ajanta Pharma posts the highest return on equity in this group at 23.3%. Sun Pharma has the largest FY26 revenue at Rs 61,674 crore, and Caplin Point Laboratories shows the fastest revenue growth with a 15.2% compound annual rate. A useful habit with Africa, Latin America and specialty drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several domestic and emerging market pharma stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Africa, Latin America and Specialty Drug Stocks

Every theme carries risks that deserve a check before any decision. For these Africa, Latin America and specialty drug stocks, the main points are: Long-term branded generics and specialty medicines shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio. Tracking promoter holding and management commentary adds context when you study branded generics and specialty medicines shares.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Pricing pressure. Generic prices can change by market.
• Currency moves. Export earnings move with the rupee.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter Africa, Latin America and specialty drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Africa, Latin America and Specialty Drug Stocks

Africa, Latin America and specialty drug stocks suit investors who prefer to study business strength before price moves. Ajanta Pharma, Caplin Point Laboratories and Sun Pharma each have a clear plan to grow. Based on the 27 October 2026 close, Ajanta Pharma trades at Rs 3,353.6, Caplin Point Laboratories at Rs 2,352.4 and Sun Pharma at Rs 1,751.2. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these Africa, Latin America and specialty drug stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track Africa, Latin America and specialty drug stocks, set price alerts and get research-backed stock ideas.

What are Africa, Latin America and specialty drug stocks?

Ans. Africa, Latin America and specialty drug stocks are listed pharmaceutical companies that sell branded generics in India, Africa, Asia and Latin America and also build specialty and complex generics for regulated markets. Their earnings depend on product launches, regulatory approvals, pricing and currency. This list looks at three of them, Ajanta Pharma, Caplin Point Laboratories and Sun Pharma, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.

Which Africa, Latin America and specialty drug stocks are covered in this list?

Ans. This list covers Ajanta Pharma, Caplin Point Laboratories and Sun Pharma. Based on the 27 October 2026 close, Ajanta Pharma traded at Rs 3,353.6, Caplin Point Laboratories at Rs 2,352.4 and Sun Pharma at Rs 1,751.2. Their return on equity ranges from 13.7% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.6% to 15.2%.

Why do Africa, Latin America and specialty drug stocks have a strong future roadmap in India?

Ans. Africa, Latin America and specialty drug stocks have a strong roadmap in India because wider access to medicines in emerging markets, specialty launches and a strong domestic prescription base keep widening the market for Indian pharmaceutical companies. The main drivers are as follows. Emerging markets. Branded generics reach fast-growing regions. Specialty launches. Skin and eye care products add value. Domestic base. Doctors prescribe trusted brands. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Ajanta Pharma performed financially?

Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

How has Caplin Point Laboratories performed financially?

Ans. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

How has Sun Pharma performed financially?

Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.

What risks should investors check before buying Africa, Latin America and specialty drug stocks?

Ans. Investors should check a few risks before buying Africa, Latin America and specialty drug stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of Africa, Latin America and specialty drug stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.